Akarna Therapeutics
Cambridge
About Akarna Therapeutics
Akarna Therapeutics is a biopharmaceutical company with offices in San Diego and Cambridge (UK) that is developing novel small molecule therapeutics that target inflammatory and fibrotic diseases. Our lead program is a non-bile acid FXR agonist that is potentially a best-in-class therapeutic for the treatment of nonalcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies. Akarna’s lead candidate is currently in preclinical, IND-enabling toxicology and safety pharmacology studies with first-in-human studies planned for early 2017.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $15.0M
- Funding stage: M&A
- Last round: Series B (Feb 2016)
- Website: akarna.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Canonical: https://fsome.com/organization/akarna-therapeutics-148564 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.